REGULATORY
AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
Japan’s government funding agency for medical R&D and leading pharma trade group have joined forces to accelerate innovative drug discovery by embedding industry expertise into state-backed research programs. The Japan Agency for Medical Research and Development (AMED) and the Japan…
To read the full story
Related Article
- Four Pharma Secondees Join AMED Drug Discovery Initiative
June 1, 2026
- Ex-JPMA President Ueno Takes on New AMED Advisor Role
January 6, 2026
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





